Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q3 FY26 results · Oct–Dec 2025
Ajanta Pharma reported revenue from operations of ₹1,374.84 crore (up 20.0% from Q3 FY25) and net profit of ₹273.77 crore (up 17.6% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,374.84 | 1,146.13 | +20.0% | 1,353.73 | +1.6% |
| Other income | 24.97 | 30.44 | −18.0% | 59.34 | −57.9% |
| Total income | 1,399.81 | 1,176.57 | +19.0% | 1,413.07 | −0.9% |
| Profit before tax | 358.60 | 307.39 | +16.7% | 340.81 | +5.2% |
| Net profit for the period | 273.77 | 232.88 | +17.6% | 260.19 | +5.2% |
| EPS, basic (₹) | 21.91 | 18.60 | +17.8% | 20.83 | +5.2% |
| Net margin (%) | 19.9 | 20.3 | 19.2 |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,206.59 | 1,101.92 | +9.5% | 1,220.24 | −1.1% |
| Other income | 25.76 | 33.23 | −22.5% | 75.03 | −65.7% |
| Total income | 1,232.35 | 1,135.15 | +8.6% | 1,295.27 | −4.9% |
| Profit before tax | 322.46 | 332.15 | −2.9% | 321.97 | +0.2% |
| Net profit for the period | 245.04 | 252.45 | −2.9% | 249.53 | −1.8% |
| EPS, basic (₹) | 19.61 | 20.16 | −2.7% | 19.98 | −1.9% |
| Net margin (%) | 20.3 | 22.9 | 20.4 |
Consolidated
- Filed with BSE
- 30 Jan 2026, 15:59 IST
- Board meeting
- 30 Jan 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Jan 2026, 15:59 IST
- Board meeting
- 30 Jan 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE